Prevalence and clinical outcomes of patients with apparent treatment-resistant hypertension enrolled in Phase 2 cardiac rehabilitation

J Clin Hypertens (Greenwich). 2020 Dec;22(12):2377-2381. doi: 10.1111/jch.14057. Epub 2020 Sep 23.

Abstract

Phase 2 cardiac rehabilitation (CR) employs evidenced-based interventions to modify the risk of cardiac morbidity in its participants. The prevalence of apparent treatment-resistant hypertension (aTRH) among CR participants is unknown. A retrospective analysis of a longitudinal cohort of patients who completed CR between 2012 and 2017 was undertaken. The prevalence of hypertension was 62% (n = 311). 11% of participants with hypertension had aTRH (n = 35). Participants with aTRH exhibited lower exercise capacity (EC) before starting CR and after its completion compared to normotensive counterparts (P < .001). aTRH participants were more likely to experience a decrease in EC, even after participating in cardiac rehabilitation, compared to normotensive participants (P = .02). aTRH participants were more likely to be hospitalized or seen in the emergency department after cardiac rehabilitation completion compared to normotensive counterparts (OR: 2.85, P < .01). CR presents an opportunity to identify and appropriately care for patients with aTRH.

Keywords: cardiac rehabilitation; exercise capacity; hypertension; resistant hypertension.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Cardiac Rehabilitation*
  • Humans
  • Hypertension* / drug therapy
  • Hypertension* / epidemiology
  • Prevalence
  • Retrospective Studies
  • Risk Factors

Substances

  • Antihypertensive Agents